Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors.
Wnt signaling
cancer survival
medicinal chemistry
quinazoline
structure activity relationship
thienopyrimidine
triple-negative breast cancer
β-catenin
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
09
2022
accepted:
17
10
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
The Wnt-pathway has a critical role in development and tissue homeostasis and has attracted increased attention to develop anticancer drugs due to its aberrant activation in many cancers. In this study, we identified a novel small molecule series with a thienopyrimidine scaffold acting as a downstream inhibitor of the β-catenin-dependent Wnt-pathway. This novel chemotype was investigated using Wnt-dependent triple-negative breast cancer (TNBC) cell lines. Structure activity relationship (SAR) exploration led to identification of low micromolar compounds such as
Identifiants
pubmed: 36386148
doi: 10.3389/fphar.2022.1045102
pii: 1045102
pmc: PMC9649909
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1045102Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 Boudou, Mattio, Koval, Soulard and Katanaev.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Lett. 2019 May 1;449:45-55
pubmed: 30771433
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
J Natl Cancer Inst. 2014 Jan;106(1):djt356
pubmed: 24309006
Nature. 2003 May 22;423(6938):448-52
pubmed: 12717451
Mol Cell Ther. 2014 Sep 11;2:28
pubmed: 26056595
Front Plant Sci. 2022 Jan 13;12:805610
pubmed: 35095976
Front Immunol. 2019 Dec 20;10:2854
pubmed: 31921125
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Cancer Discov. 2021 Oct;11(10):2413-2429
pubmed: 34518209
Swiss Med Wkly. 2019 Oct 03;149:w20129
pubmed: 31579927
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Biochem J. 2011 Feb 1;433(3):435-40
pubmed: 21128903
BBA Clin. 2015 Mar 12;3:257-75
pubmed: 26676166
Bioinformatics. 2016 Sep 15;32(18):2866-8
pubmed: 27153664
Sci Rep. 2018 May 9;8(1):7329
pubmed: 29743726
Eur J Med Chem. 2021 Oct 15;222:113562
pubmed: 34116325
Drug Discov Today. 2012 Dec;17(23-24):1316-22
pubmed: 22819927
Pharmacol Ther. 2022 Oct;238:108179
pubmed: 35358569
Nucleic Acids Res. 2022 Mar 23;:
pubmed: 35325185
Mol Pharmacol. 2020 Feb;97(2):72-89
pubmed: 31787618
Discov Oncol. 2021 Oct 10;12(1):40
pubmed: 35201496
J Cancer Res Clin Oncol. 2022 Aug 17;:
pubmed: 35976445
Front Chem. 2021 Aug 12;9:664489
pubmed: 34458231
Cancer Lett. 2018 Oct 28;435:110-120
pubmed: 30098400
Oncogene. 2006 Dec 4;25(57):7492-504
pubmed: 17143293
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Nat Rev Cancer. 2021 Jan;21(1):5-21
pubmed: 33097916
J Med Chem. 2021 Apr 22;64(8):4257-4288
pubmed: 33822624
Cancer Lett. 2020 Mar 31;473:186-197
pubmed: 31560935
Anal Biochem. 2000 Jun 15;282(1):158-61
pubmed: 10860516
World J Biol Chem. 2015 Nov 26;6(4):290-300
pubmed: 26629312
Methods Cell Biol. 2019;149:57-75
pubmed: 30616827
Drug Discov Today. 2022 Mar;27(3):777-792
pubmed: 34915171
Crit Rev Eukaryot Gene Expr. 2011;21(3):207-36
pubmed: 22111711
Handb Exp Pharmacol. 2021;269:215-248
pubmed: 34455487